Paper · 41870032

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer.

Zhang Y and 8 others. Elife, 2026. Cited by 1 paper, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer. Papers, record 41870032. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41870032

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer.; PubMed
Journal: Elife; PubMed
Year: 2026; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/41870032/; PubMed
DOI: https://doi.org/10.7554/elife.104060; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13008354/; PubMed
The journal: https://conductscience.org/library/journal-index/101579614; PubMed
Citations, by iCite: 1; iCite
Revised in PubMed: 2026-08-13; PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Zhang Y	Yue	https://orcid.org/0009-0005-3041-6300
2	Wang H	Hanbing
3	Wei Y	Yutao
4	Pan Y	Yunfeng
5	Song X	Xueru
6	Shao J	Jie
7	Yu L	Lixia
8	Shi T	Tao
9	Wang Y	Yue	https://orcid.org/0000-0002-3073-2574

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Stomach Neoplasms	Major topic
Protein Tyrosine Phosphatase, Non-Receptor Type 11	Major topic
Receptor, Fibroblast Growth Factor, Type 2	Major topic
Drug Resistance, Neoplasm	Major topic
Humans
Animals
Mice
Cell Line, Tumor
Gene Amplification
Xenograft Model Antitumor Assays
Signal Transduction

Source PubMed

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Stated by
82403862	National Natural Science Foundation of China	PubMed
82403835	National Natural Science Foundation of China	PubMed
BK20230151	Jiangsu Provincial Natural Science Foundation Youth Project	PubMed
BK20240247	Jiangsu Provincial Natural Science Foundation Youth Project	PubMed
BG2024026	Jiangsu Provincial Major Science and Technology Program	PubMed
320.6750.2023-11-30	the Wu Jieping Medical Foundation Special Fund for Targeted Cancer Therapy (Youth Research Project)	PubMed
JSTJ-2025-715	Jiangsu Provincial Youth Science and Technology Talent Support Project	PubMed
YKK24084	General Project of Nanjing Health Science and Technology Development Program	PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	34,860,570	Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.	J Clin Oncol	2022	https://conductscience.org/library/papers/34860570	PubMed
2	28,303,906	Advances and challenges in targeting FGFR signalling in cancer.	Nat Rev Cancer	2017	https://conductscience.org/library/papers/28303906	PubMed
3	33,305,187	SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations.	iScience	2020	https://conductscience.org/library/papers/33305187	PubMed
4	23,696,246	FGF receptors: cancer biology and therapeutics.	Med Res Rev	2014	https://conductscience.org/library/papers/23696246	PubMed
5	30,589,534	The RTK Interactome: Overview and Perspective on RTK Heterointeractions.	Chem Rev	2019	https://conductscience.org/library/papers/30589534	PubMed
6	35,130,500	Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.	J Natl Compr Canc Netw	2022	https://conductscience.org/library/papers/35130500	PubMed
7	33,028,804	Advances in targeted therapy for esophageal cancer.	Signal Transduct Target Ther	2020	https://conductscience.org/library/papers/33028804	PubMed
8	33,687,617	Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.	Gastric Cancer	2021	https://conductscience.org/library/papers/33687617	PubMed
9	32,928,921	Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.	Cancer Res	2020	https://conductscience.org/library/papers/32928921	PubMed
10	27,179,038	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.	Cancer Discov	2016	https://conductscience.org/library/papers/27179038	PubMed

1 to 10 of 51

See all 51 references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMID	Title	Journal	Year	In Papers
42,531,194	Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer: Multi-pathway signaling modulation in vitro.	PLoS One	2026	https://conductscience.org/library/papers/42531194

Source PubMed

Genes33

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
AFP	174	PubTator's text mining	https://conductscience.org/library/genes/174	NCBI Gene
AKT1	207	PubTator's text mining	https://conductscience.org/library/genes/207	NCBI Gene
ARID1A	8,289	PubTator's text mining	https://conductscience.org/library/genes/8289	NCBI Gene
CCND1	595	PubTator's text mining	https://conductscience.org/library/genes/595	NCBI Gene
CCNE1	898	PubTator's text mining	https://conductscience.org/library/genes/898	NCBI Gene
CD274	29,126	PubTator's text mining	https://conductscience.org/library/genes/29126	NCBI Gene
CD28	940	PubTator's text mining	https://conductscience.org/library/genes/940	NCBI Gene
CD4	920	PubTator's text mining	https://conductscience.org/library/genes/920	NCBI Gene
CD8A	925	PubTator's text mining	https://conductscience.org/library/genes/925	NCBI Gene
CDH1	999	PubTator's text mining	https://conductscience.org/library/genes/999	NCBI Gene

1 to 10 of 33

See all 33 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41870032

GET https://conductscience.org/api/papers/v1/41870032/references?page=2

API reference For AI assistants